Recent
Press/Media Releases:
CYTOCHROMA
APPOINTS R. RICHARD WIELAND II AS CFO
May 12, 2008
CYTOCHROMA OPENS
U.S. HEADQUARTERS IN ILLINOIS
April 29, 2008
CYTOCHROMA INITIATES
PHASE I/II CLINICAL TRIAL OF CTAP101 CAPSULES FOR VITAMIN
D INSUFFICIENCY IN CHRONIC KIDNEY DISEASE
November 20, 2007
CYTOCHROMA ANNOUNCES
APPOINTMENT OF GORDON NGAN, CFA, MBA AS EXECUTIVE DIRECTOR, CORPORATE
DEVELOPMENT
August 23, 2007
JOEL
Z. MELNICK, MD JOINS CYTOCHROMA AS VICE PRESIDENT, CLINICAL & REGULATORY
AFFAIRS
August 13, 2007
CYTOCHROMA REPORTS POSITIVE
PHASE I CLINICAL DATA FOR CTA018 INJECTION
June 28, 2007
CYTOCHROMA AND GENZYME
SETTLE LAWSUIT
April 16, 2007
CYTOCHROMA INC.
ANNOUNCES COMPLETION OF $3 MILLION RAISE
March 29, 2007
CYTOCHROMA APPOINTS
CO-FOUNDER DR. P. MARTIN PETKOVICH AS FULL-TIME CHIEF SCIENTIFIC
OFFICER
March 12, 2007
CYTOCHROMA COMPLETES
ENROLLMENT IN PHASE II PSORIASIS TRIAL
March 06, 2007
CYTOCHROMA INC.
ANNOUNCES COMPLETION OF $21 MILLION FINANCING ROUND
January 17, 2007
CYTOCHROMA
INC. AND AOVATECHNOLOGIES, INC., SIGN LICENSE AGREEMENT
January 8, 2007
CYTOCHROMA INITIATES
PHASE II CLINICAL TRIAL FOR PSORIASIS
November 13, 2006
MEDIA STATEMENT:
CYTOCHROMA MOVES FORWARD DESPITE GENZYME LAWSUIT
August 22, 2006
CYTOCHROMA ACQUIRES
PROVENTIV THERAPEUTICS TO COMMERCIALIZE NEW VITAMIN D PRODUCTS
FOR CKD MARKET
June 29, 2006
CYTOCHROMA’S VITAMIN
D ANALOG SHOWS PROMISING RESULTS IN MULTIPLE SCLEROSIS MODEL
June 07, 2006
CYTOCHROMA ANNOUNCES
SIGNIFICANT RESULTS WITH CTA002, A VITAMIN D ANALOG AND ENZYME
INHIBITOR, IN A PROSTATE CANCER MODEL
May 10, 2006
CTA002, A NOVEL VITAMIN
D ANALOG, SHOWS SIGNIFICANT ANTI-TUMOR ACTIVITY IN HUMAN
NEUROBLASTOMA
April 26, 2006
CYTOCHROMA GRANTED FDA
APPROVAL TO COMMENCE PHASE II CLINICAL TRIAL FOR NOVEL TOPICAL
TREATMENT OF PSORIASIS
February 20, 2006
< Archives > |
about
us